ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Glaucine suppresses IL-16/CD4 to alleviate neuropathic pain via spinal p56
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Effective drugs for neuropathic pain are urgently needed. Natural compound glaucine from Corydalis Rhizoma inhibits spinal sensitization and alleviates neuropathic pain, yet its exact analgesic mechanism remains unclear. A rat model of neuropathic pain was established via chronic constriction injury (CCI) of the sciatic nerve. Behavioral tests (von Frey and Hargreaves tests) were used to assess neuropathic pain symptoms by evaluating mechanical allodynia and thermal hyperalgesia. Primary spinal neurons, glia, and peritoneal macrophages were cultured for in vitro analysis. Molecular pathways were examined using RNA sequencing, Western blot, qRT-PCR, and immunofluorescence. Glaucine significantly suppressed spinal IL-16 expression in CCI rats, and its analgesic effects were reversed by exogenous IL-16 administration. RNA-seq and protein assays confirmed IL-16 upregulation in injured peripheral nerves and spinal cord. Critically, inhibiting IL-16/CD4 signaling at peripheral and spinal levels alleviated neuropathic pain. Dual immunofluorescence in vivo and in vitro revealed IL-16/CD4 localization in neurons, and spinal IL-16 inhibition reduced neuronal activation. Calcium fluorescence imaging further demonstrated that spinal IL-16 blockade reduced spinal neuronal excitability through restraining the NMDA receptor. The IL-16 induced phosphorylation of NMDA receptor was mediated by lymphocyte-specific protein tyrosine kinase (p56
Indexed as
Identifiers
41269295What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.